BHVN Price Prediction Next Week
Analysis and Insights
Technical Analysis:
Biohaven Ltd (BHVN) is currently trading at $30.23, with a Relative Strength Index (RSI) of 34.36, indicating oversold conditions. The stock is approaching the lower Bollinger Band, suggesting potential support and a possible reversal. The MACD is bearish, but the stock is near oversold levels, which could indicate a short-term bounce.
News Sentiment and Recent Developments:
- Oversold Conditions: BHVN has entered oversold territory with an RSI of 29.7, suggesting potential exhaustion of selling pressure.
- Increased Investor Interest: Searches for BHVN have surged by 102%, indicating heightened investor interest.
- Weight-Loss Drug Market: Biohaven is developing a myostatin-targeting agent for obesity, but its recent Phase 3 trial failed to meet expectations.
Fibonacci Levels:
The Fibonacci levels suggest key support at $27.40 and resistance at $30.79. The stock is currently trading near the lower end of this range, with a pivot point at $28.70.
Price Prediction:
Given the oversold conditions and potential investor interest, BHVN is likely to experience a short-term rebound. The stock is expected to reach $30.50 by the end of the next trading week.
Recommendation:
Buy BHVN at current levels, as the stock is near support and oversold conditions suggest a potential reversal.
BHVN Similar Chart Price Prediction
The price of BHVN is predicted to go up 0.72%, based on the high correlation periods with AXS. The similarity of these two price pattern on the periods is 98.51%.
BHVN
AXS
Up: 0.72%Similarity: 98.51%
BHVN Revenue Forecast
BHVN EPS Forecast
BHVN FAQs
What is BHVN revenue forecast for next quarter？
BHVN Analyst's Forecast
Terence Flynn
Morgan Stanley
Buy
2025-03-07
Price Target
$69 → $63
Upside
+108.54%
Morgan Stanley lowered the firm's price target on Biohaven to $63 from $69 and keeps an Overweight rating on the shares. Biohaven reported Q4 earnings on March 3 and provided "mixed" data updates for BHV-1300 and BHV-7000, with the updates for BHV-1300 being positive, as it achieved sustained reductions in total IgG of up to 84%, while the BHV-7000 Phase 2 data was negative, as it failed to reach statistical significance from the comparator on the Young Mania Rating Scale in bipolar mania, the analyst tells investors in a research note. The firm removed BHV-7000 bipolar indication from its model and says it expects the primary focus for the stock to remain on upcoming FDA action on Troriluzole for Spinocerebellar Ataxia this summer.
David Hoang
Deutsche Bank
Strong Buy
2025-02-11
Price Target
$65
Upside
+50.32%
Leonid Timashev
RBC Capital
Buy
2024-12-04
Price Target
$58 → $61
Upside
+31.49%
